The COVID-19 pandemic drove huge shifts in clinical trial practice and the transformation is expected to continue even after the global health emergency abates. Industry leaders sharing their predictions around clinical development homed in on decentralized trials, digitization and data tools as key topics for 2022.
Evolution of clinical trials was a major theme among executives who at the end of 2021 shared their predictions for 2022. Remote, or decentralized, trials was a common talking point, as was the harnessing of technological advances in capturing and analyzing data.
Ross Pettit, deputy president of Eisai Co., Ltd. precision oncology subsidiary H3 Biomedicine Inc, summed up some of...
The company is expecting US FDA approval of the drug in a bigger indication, major depressive disorder, later this year.
The Kevin Tang-led firm will pay $4.38 per share for Cargo, which laid off most of its workforce following the failure of a Phase II CAR-T trial.
Evaluate’s second quarter data show that VC rounds of $100m or more totaled $2.36bn, down from $5.25bn in Q2 of 2024. Overall, the Q2 total dropped year-over-year to $4.92bn from $7.95bn.
